NIH Refuses To Release Details Of COVID-19 Vaccine Royalty Agreement [zero hedge]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: zero hedge
NIH Refuses To Release Details Of COVID-19 Vaccine Royalty Agreement Authored by Zachary Stieber via The Epoch Times (emphasis ours), The U.S. National Institutes of Health (NIH) is refusing to release additional information about an agreement it reached over a COVID-19 vaccine that has earned it at least $400 million. Syringes of Moderna COVID-19 vaccines at a vaccination site in Los Angeles, on Feb. 16, 2021. (Apu Gomes/AFP via Getty Images) The NIH declined to provide any materials in response to a Freedom of Information Act request from The Epoch Times. “ The NIH withholds the entirety of the records as they are protected from release ,” Gorka Garcia-Malene, an NIH officer, told The Epoch Times in a letter. She cited an exemption outlined in the act that allows government agencies to partially or fully withhold information. “In this case, exemption 3 incorporates 35 U.S.C. 209 (f), which reads in relevant part, ‘No Federal agency shall grant any license under a patent or patent ap
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Moderna, Inc. (NASDAQ: MRNA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $91.00 to $106.00. They now have a "hold" rating on the stock.MarketBeat
- Moderna, Inc. (NASDAQ: MRNA) had its price target raised by analysts at Royal Bank of Canada from $125.00 to $135.00. They now have an "outperform" rating on the stock.MarketBeat
- Moderna, Inc. (NASDAQ: MRNA) had its price target raised by analysts at Oppenheimer Holdings Inc. from $142.00 to $163.00. They now have an "outperform" rating on the stock.MarketBeat
- Thousands Believe Covid Vaccines Harmed Them. Is Anyone Listening? [The New York Times]The New York Times
- Moderna reports $1.2bn net loss in Q1 2024 [Yahoo! Finance]Yahoo! Finance
MRNA
Earnings
- 5/2/24 - Beat
MRNA
Sec Filings
- 5/3/24 - Form 4
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- MRNA's page on the SEC website